During the last session, Hims & Hers Health Inc (NYSE:HIMS)’s traded shares were 42.62 million, with the beta value of the company hitting 1.39. At the end of the trading day, the stock’s price was $59.18, reflecting an intraday gain of 27.71% or $12.84. The 52-week high for the HIMS share is $46.49, that puts it up 21.44 from that peak though still a striking 84.56% gain since the share price plummeted to a 52-week low of $9.14. The company’s market capitalization is $12.93B, and the average trade volume was 15.12 million shares over the past three months.
Hims & Hers Health Inc (HIMS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.25. HIMS has a Sell rating from 0 analyst(s) out of 13 analysts who have looked at this stock. 5 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.21.
Hims & Hers Health Inc (NYSE:HIMS) trade information
Hims & Hers Health Inc (HIMS) registered a 27.71% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 27.71% in intraday trading to $59.18, hitting a weekly high. The stock’s 5-day price performance is 46.23%, and it has moved by 125.79% in 30 days. Based on these gigs, the overall price performance for the year is 494.77%.
The consensus price target of analysts on Wall Street is $25, which implies a decrease of -136.72% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20 and $38 respectively. As a result, HIMS is trading at a premium of 35.79% off the target high and 66.2% off the low.
Hims & Hers Health Inc (HIMS) estimates and forecasts
In the rating firms’ projections, revenue will increase 67.63% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 469.68M as predicted by 13 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 492.44M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 246.62M and 278.17M respectively. In this case, analysts expect current quarter sales to grow by 90.45% and then jump by 77.03% in the coming quarter.
While earnings are projected to return 592.48% in 2025.
HIMS Dividends
Hims & Hers Health Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 14.57 million shares, is of BLACKROCK INC.’s that is approximately 6.8278% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $294.25 million.
